Abstract
Summary
The incidence of clinical fractures and the associated factors were assessed in patients with systemic lupus erythematosus (SLE) versus matched controls. We found an increased fracture risk in SLE patients compared to controls. Glucocorticoid use, longer disease duration, neuropsychiatric disease complications and previous osteoporotic fractures were identified as associated factors.
Introduction
The aims of this study were to estimate the risk of clinical fractures in patients with SLE versus matched controls and to evaluate the risk factors associated with clinical fractures in SLE.
Methods
This is a population-based cohort study using the Clinical Practice Research Datalink (from 1987–2012). Each SLE patient (n = 4,343) was matched with up to six controls (n = 21,780) by age and sex. Clinical fracture type was stratified according to the WHO definitions into osteoporotic and non-osteoporotic fracture. Cox proportional hazards calculated relative rates (RR) of clinical fracture and time interaction terms to evaluate the timing patterns of fracture. Clinical fracture rates in SLE patients, stratified by age, gender, type of fracture, disease duration and therapy variables, were compared with those rates in controls.
Results
Follow-up durations were 6.4 years in SLE patients and 6.6 years in controls. SLE patients had a 1.2-fold increased clinical fracture risk compared to controls (adjusted RR = 1.22, 95% CI = 1.05–1.42), and the risk further increased with a longer disease duration. Glucocorticoid (GC) use in the previous 6 months raised the risk of clinical fracture (adjusted RR = 1.27, 95% CI = 1.02–1.58). Cerebrovascular events, seizures and previous osteoporotic fractures were identified as predictors of clinical fractures.
Conclusions
We found an increased risk of clinical fracture in SLE patients compared to controls. GC use in the previous 6 months and longer disease duration are associated with the increased fracture risk in SLE. Patients with neuropsychiatric organ damage or previous osteoporotic fractures are also at increased risk of the occurrence of clinical fractures.
Similar content being viewed by others
References
Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St. Pierre Y, Clarke A, Ramsey-Goldman R (2006) Mortality in systemic lupus erythematosus. Arthritis Rheum 54:2550–2557
Kalla AA, Fataar AB, Jessop SJ, Bewerunge L (1993) Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 36:1726–1734
Mok CC, Mak A, Ma KM (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14:106–112
Boyanov M, Robeva R, Popivanov P (2003) Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 22:318–323
Uaratanawong S, Deesomchoke U, Lertmaharit S, Uaratanawong S (2003) Bone mineral density in premenopausal women with systemic lupus erythematosus. J Rheumatol 30:2365–2368
Bultink IE (2012) Osteoporosis and fractures in systemic lupus erythematosus. Arthritis Care Res 64:2–8
Bultink IE, Lems WF, Kostense PJ, Dijkmans BA, Voskuyl AE (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050
Li EK, Tam LS, Griffith JF, Zhu TY, Li TK, Li M, Wong KC, Chan M, Lam CW, Chu FS, Wong KK, Leung PC, Kwok AY (2009) High prevalence of asymptomatic vertebral fractures in Chinese women with systemic lupus erythematosus. J Rheumatol 36:1646–1652
Borba VZ, Matos PG, da Silva Viana PR, Fernandes A, Sato EI, Lazaretti-Castro M (2005) High prevalence of vertebral deformity in premenopausal systemic lupus erythematosus patients. Lupus 14:529–533
Mendoza-Pinto C, Garcia-Carrasco M, Sandoval-Cruz H, Muñoz-Guarneros M, Escárcega RO, Jiménez-Hernández M, Munguía-Realpozo P, Sandoval-Cruz M, Delezé-Hinojosa M, López-Colombo A, Cervera R (2009) Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol 28:579–585
Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, Manzi S (1999) Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum 42:882–990
Fangtham M, Petri M (2009) Predictors of osteoporotic fracture in SLE [abstract]. Arthritis Rheum 60 Suppl:S110
Yee CS, Crabtree N, Skan J, Amft N, Bowman S, Situnayake D, Gordon C (2005) Prevalence and predictors of fragility fractures in systemic lupus erythematosus. Ann Rheum Dis 64:111–113
Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Ramsey-Goldman R (2007) Self-reported fractures and associated factors in women with systemic lupus erythematosus. J Rheumatol 34:2018–2023
Ekblom-Kulberg S, Kautiainen H, Alha P, Leirisalo-Repo M, Julkunen H (2013) Frequency of and risk factors for symptomatic bone fractures in patients with systemic lupus erythematosus. Scand J Rheumatol 42:390–393
Wang SH, Chang YS, Liu CJ, Lai CC, Chen WS, Chen TJ, Wang SJ (2013) Systemic lupus erythematosus is associated with a higher risk of cervical but not trochanteric hip fracture: a nationwide population-based study. Arthritis Care Res (Hoboken) 24:1817–1826
Zonana-Nacach A, Barr SG, Magder LS, Petri M (2000) Damage in systemic lupus erythematosus and its association with corticosteroids. Arthritis Rheum 43:1801–1808
Rhew EY, Lee C, Eksarko P, Dyer AR, Tily H, Spies S, Pope RM, Ramsey-Goldman R (2008) Homocysteine, bone mineral density, and fracture risk over 2 years of followup in women with and without systemic lupus erythematosus. J Rheumatol 35:230–236
Weiss RJ, Wick MC, Ackermann PW, Montgomery SM (2010) Increased fracture risk in patients with rheumatic disorders and other inflammatory diseases: a case–control study with 53,108 patients with fractures. J Rheumatol 37:2247–2250
Herrett E, Thomas SL, Schoonen WM, Smeeth L, Hall AJ (2010) Validation and validity of diagnoses in the General Practice Research Database: a systematic review. Br J Clin Pharmacol 69:4–14
Khan NF, Harrison SE, Rose PW (2010) Validity of diagnostic coding within the General Practice Research Database: a systematic review. Br J Gen Pract 60:e128–e136
van Staa TP, Abenhaim L, Cooper C, Zhang B, Leufkens HG (2000) The use of a large pharmacoepidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results. Pharmacoepidemiol Drug Saf 9:359–366
Lalmohamed A, Welsing PM, Lems WF, Jacobs JW, Kanis JA, Johansson H, de Boer A, de Vries F (2012) Calibration of FRAXⓇ 3.1 to the Dutch population with data on the epidemiology of hip fractures. Osteoporos Int 23:861–869
Pouwels S, Lalmohamed A, Leufkens B, de Boer A, Cooper C, van Staa T, de Vries F (2009) Risk of hip/femur fracture after stroke: a population-based case–control study. Stroke 40:3281–3285
de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP (2007) Use of beta-2 agonists and risk of hip/femur fracture: a population-based case–control study. Pharmacoepidemiol Drug Saf 16:612–619
de Vries F, Bracke M, Leufkens HG, Lammers JW, Cooper C, van Staa TP (2007) Fracture risk with intermittent high-dose oral glucocorticoid therapy. Arthritis Rheum 56:208–214
Pouwels S, van Staa TP, Egberts AC, Leufkens HG, Cooper C, de Vries F (2009) Antipsychotic use and the risk of hip/femur fracture: a population-based case–control study. Osteoporos Int 20:1499–1506
Pouwels S, Bazelier MT, de Boer A, Weber WE, Neef C, Cooper C, de Vries F (2013) Risk of fracture in patients with Parkinson’s disease. Osteoporos Int 24:2283–2290
Isenberg DA, Rahman A, Allen E, Farewell V, Akil M, Bruce IN, D’Cruz D, Griffiths B, Khamashta M, Maddison P, McHugh N, Snaith M, Teh LS, Yee CS, Zoma A, Gordon C (2005) BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 44:902–906
Anonymous (2012) ATC Classification Index with DDDs 2002. Nydalen: WHO Collaborating Centre for Drug Statistics Methodology Norwegian Institute of Public Health
Gladman D, Ginzler E, Goldsmith C, Fortin P, Liang M, Urowitz M, Bacon P, Bombardieri S, Hanly J, Hay E, Isenberg D, Jones J, Kalunian K, Maddison P, Nived O, Petri M, Richter M, Sanchez-Guerrero J, Snaith M, Sturfelt G, Symmons D, Zoma A (1996) The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum 39:363–369
Lalmohamed A, Vestergaard P, Klop C, Grove EL, de Boer A, Leufkens HG, van Staa TP, de Vries F (2012) Timing of acute myocardial infarction in patients undergoing total hip or knee replacement: a nationwide cohort study. Arch Intern Med 19:1229–1235
Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C (2000) Use of oral corticosteroids and risk of fractures. J Bone Miner Res 15:993–1000
Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta M (2010) Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 69:20–28
Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108
Mok CC, Ying SK, To CH, Ma KM (2008) Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone 43:327–331
Jacobs J, Korswagen LA, Schilder AM, van Tuyl LH, Dijkmans BA, Lems WF, Voskuyl AE, Bultink IEM (2013) Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 24:1827–1833
Mazziotti G, Canalis E, Giustina A (2010) Drug-induced osteoporosis: mechanisms and clinical implications. Am J Med 123:877–884
Somers EC, Thomas SL, Schoonen WM, Hall AJ (2007) Incidence of systemic lupus erythematosus in the United Kingdom, 1990–1999. Arthritis Rheum 57:612–618
Conflicts of interest
IB received speaking fees from Servier Laboratories and MSD.
NH received research support/honoraria from Amgen, Alliance for Better Bone Health, Eli Lilly, Servier Laboratories, Proctor and Gamble, Nycomed, Sanofi-Aventis and Shire.
CC received consulting and speaker fees from Amgen, GSK, Alliance for Better Bone Health, Eli Lilly, Pfizer, Servier Laboratories, MSD, Novartis, Medtronic and Roche.
WL received research and speaking fees from Amgen, Eli Lilly, MSD, Servier Laboratories and Novartis.
FV consults to MSD Netherlands on a voluntary basis and has not received any fees or reimbursements.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Bultink, I.E.M., Harvey, N.C., Lalmohamed, A. et al. Elevated risk of clinical fractures and associated risk factors in patients with systemic lupus erythematosus versus matched controls: a population-based study in the United Kingdom. Osteoporos Int 25, 1275–1283 (2014). https://doi.org/10.1007/s00198-013-2587-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00198-013-2587-z